Dr Mike Bromley talks about the role of Manchester University in the research and development of new antifungal drugs, followed by Dr Iain Page talking about our research projects in Africa that have the potential to reveal much larger numbers of people suffering from Chronic Pulmonary Aspergillosis (CPA) than is currently thought.
Call Girls Coimbatore Just Call 9907093804 Top Class Call Girl Service Available
New antifungals and TB research
1. L E D B Y G R A H A M A T H E R T O N
S U P P O R T E D B Y
G E O R G I N A P O W E L L , D E B B I E K E N N E D Y & D E B H A W K E R
N A C C E N T R E M A N A G E R C H R I S H A R R I S
A S P E R G I L L U S R E S E A R C H – M I K E B R O M L E Y
A F R I C A N A S P E R G I L L O S I S – I A I N P A G E
N A T I O N A L A S P E R G I L L O S I S C E N T R E
U H S M
M A N C H E S T E R
Support Meeting for
Aspergillosis Patients & Carers
Fungal Research Trust
2. Car Parking
£3 all day in the Nightingale Car Park (opposite
NWLC)
Leave note in your windscreen saying
North West Lung Centre Delegate
3. Programme
1.30 Mike Bromley – Aspergillosis Research
1.55 Iain Page – Our work in Gulu, Africa
2.15 Carers Discussion (Break)
2.30 Patients Discussion (Break)
2.45 Group discussion/Requests for information
Itraconazole toxicity – risk of heart problems
Low – allergy gardening (Book)
Artificial organs – kidney
Food for patients meeting?
Damp homes – do you see damp/moulds?
Travel
3.15 Q & A from the floor or online
5. Do we need new anti-fungals?
• Invasive fungal diseases are common, debilitating, and
difficult to treat
• Few classes of drugs to treat invasive fungal disease
– Azoles, echinocandins, polyenes, 5FC
• Limited range of targets involved
• Drug toxicities/ drug-drug interactions / bioavailability
• Emerging resistance
– Particularly with reference to azoles and 5FC
• Unmet need
– Zygomycetes, Fusarium
7. The importance of fungal disease
• Fungal diseases have an enormous global
financial burden
– $60 billion damage to rice, wheat and maize crops
– $12.2 billion market for antifungal therapeutics
• Systemic human disease
– 37% market for therapeutics for invasive disease
(2010)
8. Is it financially viable?
Product/
Brand name
Generic name Class Company
Patent expiry
(US)
Peak annual
sales
(Million USD)
Ambisome
Liposomal
amphotericin B
Polyene Astellas/ Gilead Expired 2004 550
Abelcet
Lipid complex
amphotericin B
Polyene Elan/ Enzon Expired 2003 --
Cancidas Caspofungin Echinocandin Merck & Co Mar 2013 500
Diflucan Fluconazole Azole Pfizer Expired 2004 1200
Eraxis Anidulafungin Echinocandin Pfizer 2015 n/a
Mycamine Micafungin Echinocandin Astellas Sep 2015 350
Noxafil Posaconazole Azole
Schering-
Plough
Apr 2018 n/a
Sporanox Itraconazole Azole Janssen Expired 2000 900
Vfend Voriconazole Azole Pfizer May 2016 750
DataMonitor, 2007.
9. Current antifungal classes
Class Target Discovered Drug
Azole Lanosterol 14DM 1944 Benzimidazole
Polyene Membrane 1950 Nystatin
Candins Glucan synthase 1974 Echinocandin B
Pyrimidine
analogue
Pyrimidine biosynthesis 1961 Flucytosine
10. Commercial retrenchment from anti-
infective discovery
• Only a few major pharmaceutical companies are
currently operating anti-infective programs
– Highlights a change in the way that all drug discovery is
going
– Emphasis is now on small companies and Universities to
perform the early stage research function
11. The stages of drug discovery
Pre-clinical drug
discovery
GSK
$70 million
No P1 drug
12. Antifungals in development
Compound Drug Target Status Company
Isavuconazole Lanosterol 14DM Phase III Basilea/Astellas
KP-103 Lanosterol 14DM Phase III Kaken
SPK-843 Membrane Phase III Proaparts
Mycograb HSP90 Phase II Novartis/NeuTec
Icofungipen Isoleucyl-t-RNA synthase Phase II Plivia/Bayer
MK-3118 Glucan synthase Phase I Merck
Aminocandin Glucan synthase Phase I Novexel/AstraZeneca
FG-3622 Undisclosed Phase I F2G
Corifungin Membrane Phase I Acea Biotech
T-2307 Mitochondria Phase I Toyama
MGCD290 HOS2 (HDAc) Phase I MethylGene
EV-086 Undisclosed Preclinical Evolva
Ambruticin analog(s) Osmoregulatory system Preclinical Kosan
D75-4590 Glucan synthase Preclinical Daiichi Sankyo
VT1161 Lanosterol 14DM Preclinical Viamet
Sordarin analog(s)
FR290581
EF-2 Ribosome complex Preclinical Astellas
E1210 GWT1 (GPI-anchor) Preclinical Eisai
17. How does the drug kill the Aspergillus
• We can used advanced biological technologies to
find out how…..
• By examining the genetic (DNA) makeup of the
fungus and seeing how it responds
• We have to make sure that the mechanism of action
wont kill the patient!!!
• We compare the fungal DNA to human DNA
18. Once we know how the drug works we can do
some fancy stuff
Cyp51A
20. So what next?
• EU is actively funding anti-infectives research
– IMI
• Discovery and development of new drugs combating Gram
negative infections
• Combating resistant Enterobacteriaceae, Acinetobacter,
Pseudomonas, C. difficile and MRSA
– FP7-HEALTH
• SYBARIS
• ALLFUN
– FP7-HEALTH-2013-INNOVATION-2 (2013)
• NOFUN (Development of NOvel anti-FUNgals)
21. What we hope will come from NOFUN
• NOFUN will develop the highly active and
selective drugs which have novel mechanism
of action
• We will identify a candidate for GLP toxicology
22. Paul Bowyer
Jane Gilsenen
Lydia Tabenero
David Denning
Darel Macdonald
Anna Johns
Luigina Romani (Perugia)
Duccio Cavieilari (Firenze)
Ivo Gut (Barcelona)
Misha Kapucheski (EBI)
Acknowledgements
Jean-Paul Latge
Nick Read
Elaine Bignell
Mike Birch
Jason Oliver
23. Survey of Pulmonary
Aspergillosis in association with
TB and HIV in Uganda
Chief Investigator - Dr Iain
Page, Clinical Research
Fellow, University of Manchester
24. Chronic Pulmonary Aspergillosis
• Patients deteriorate over many years
• Cough, Haemoptysis, weight loss, breathlessness
and profound fatigue common
• Diagnostic criteria
– Symptoms as above
– Abnormal CXR or CT (cavitation is main feature)
– Positive Antibodies to Aspergillus in serum
• Precipitins and Aspergillus Specific IgG commonly used
• Often associated with underlying lung damage /
cavitation
– E.g. TB or COPD
25. Chronic Necrotizing Pulmonary
Aspergillosis
• Sub-acute illness
• Deterioration and death within few weeks – months
without treatment
• Associated with AIDS
• Mimics smear negative TB, PCP etc.
• Often misdiagnosed in well resourced settings
• CXR often abnormal but can be non-specific
• Aspergillus antibody may be negative
• Aspergillus antigen tests may be positive on BAL or
blood
– E.g. Galactomannan or investigational lateral flow device
26. Existing evidence for CPA in
association with TB
• Single UK MRC survey in 1968
– Looked at pts with cavities on CXR post TB
– 25% had positive Aspergillus Precipitans 1 yr post TB
• International predicted rates (Denning et al 2011)
– 36 million cured of TB worldwide 1995-2008
– 22% South African patients have cavities post TB
– 1.1 million cases CPA predicted worldwide
– 100,000 new cases annually in African
– Prevalence of 43 per 100,000 in DRC
30. Aims of the study
• Establish the prevalence of pulmonary
aspergillosis in the following groups of
patients in Gulu successfully treated for TB in
the last 7 years
• Identify or develop a simple point of care test
that (along with CXR) can diagnose CPA in
Africans
• Identify environmental and genetic risk factors
for CPA in Africans
31. Potential follow on studies
• Prospective study, lasting at least 2 years to
identify the frequency of developing CPA after
TB diagnosis and it’s impact on morbidity and
mortality
• Treatment trials of anti fungal drugs in Africa
to establish efficacy and safety with (limited
monitoring tests)
32.
33.
34.
35.
36.
37.
38.
39.
40.
41.
42.
43.
44.
45.
46.
47.
48.
49. Carer Support www.nhs.uk/carersdirect
Often neglected group – all attention given to patient
Highlighted by a recent email to the Yahoo support
group – an Australian man who has watched his
active wife become much less mobile and unable to
enjoy life as they did. They have eventually found
new ways to enjoy their time together. Read the story
at
http://patientswithaspergillosis.wikispaces.com/Fro
m+a+carers+perspective
50. Carers group
Most of us are carers for a short time – not many
volunteer or even know it is coming
Look after your own health
Have your own life too – don‟t let it be „taken over‟
Hobbies
Educate yourself about the illness that the person
you care for has – improves understanding
51. Patients group
Saline nebulisers and their effectiveness
Media portraying aspergillosis as easy to cure
What is important to you isn‟t always obvious to your
carer
When you are ill patience is inevitably shortened!
52. Whole group
At the end of the day it is important to spend time
together , finding things you can still both do –
whether you are a couple, child/parent or even just
friends
Gardening tips – reference book
Topics?
Questions?
53. Travel
Clear trip with your doctor first!
Organise carrying oxygen with your airline in advance -
some will support you better than others!
Travel insurance (Staysure, Unique (asthmaUK),
http://www.moneysupermarket.com/travel-insurance/pre-
existing-medical-conditions/)
Please give full info about ALL your medical conditions on
your proposal. If you give only partial truth and need to
claim, your whole policy might be made invalid and you
won't get anything.
http://www.aspergillus.org.uk/newpatients/travel.html
55. Travel – transporting drugs
There are a variety of bags marketed that can
maintain cool temperatures for up to 24 hours –
search for bags used by diabetics
http://www.diabetes.co.uk/diabetic-
products/medifridge.html
56. Q & A
Questions?
Areas of interest online
Mouldy homes – new guidelines – see Asp Website
Itraconazole toxicity – risk of heart problems
Low – allergy gardening (books purchased)
Artificial organs – kidney
Food for patients meeting?
Damp homes – do you see damp/moulds?
Travel
57. Itraconazole and Heart Failure
Patients NEW to itraconazole should be aware of the
possibility of heart problems
Patietns who have been taking itraconazole for over
6 – 12 months with no problems should not develop
problems in future
ALL should be watchful for signs such as:
58. Itraconazole and Heart Failure
The symptoms of heart failure can vary from
person to person. The main symptoms are
breathlessness, extreme tiredness, and ankle
swelling, which may extend up the legs.
These symptoms may be caused by conditions other
than heart failure, and sometimes there may be more
than one cause for them.
http://www.nhs.uk/Conditions/Heart-
failure/Pages/Symptoms.aspx
If in any doubt see your doctor
61. Regrown organs - progress
Kidney – complex organ
Has been stripped down & rebuilt using stem cells
(rat) and then re-implanted into host
Works with 5-10% efficiency compared with original
– thought to be sufficient to avoid transplant!
62. Food for Meeting
Can‟t transfer funds to research
Funds come out of NAC/NHS „hospitality‟ funds
Could do less – tea & biscuits?
63. Thank You
“The best chance we have of beating this illness is to
work together”
Living with it, Working with it, Treating it
Fungal Research Trust